Cargando…
Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
Introduction: Data are limited on antibody response to the ChAdOx1 nCoV-19 vaccine (AZD1222; Covishield(®)) in cirrhosis. We studied the antibody response following two doses of the ChAdOx1 vaccine, given 4–12 weeks apart, in cirrhosis. Methods: Prospectively enrolled, 131 participants (71% males; a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696004/ https://www.ncbi.nlm.nih.gov/pubmed/36366346 http://dx.doi.org/10.3390/vaccines10111837 |
_version_ | 1784838207243812864 |
---|---|
author | Goel, Amit Verma, Alka Tiwari, Prachi Katiyar, Harshita Aggarwal, Amita Khetan, Dheeraj Mayank, Kishore, Ravi V. Krishna Kumar, Pankaj Singh, Thakur Prashant Sheikh, Sabreena Vaishnav, Manas Pathak, Piyush Shalimar, |
author_facet | Goel, Amit Verma, Alka Tiwari, Prachi Katiyar, Harshita Aggarwal, Amita Khetan, Dheeraj Mayank, Kishore, Ravi V. Krishna Kumar, Pankaj Singh, Thakur Prashant Sheikh, Sabreena Vaishnav, Manas Pathak, Piyush Shalimar, |
author_sort | Goel, Amit |
collection | PubMed |
description | Introduction: Data are limited on antibody response to the ChAdOx1 nCoV-19 vaccine (AZD1222; Covishield(®)) in cirrhosis. We studied the antibody response following two doses of the ChAdOx1 vaccine, given 4–12 weeks apart, in cirrhosis. Methods: Prospectively enrolled, 131 participants (71% males; age 50 (43–58); alcohol-related etiology 14, hepatitis B 33, hepatitis C 46, cryptogenic 21, autoimmune 9, others 8; Child–Turcott–Pugh class A/B/C 52/63/16). According to dose intervals, the participants were grouped as ≤6 weeks (group I), 7–12 weeks (group II), and 13–36 weeks (group III). Blood specimens collected at ≥4 weeks after the second dose were tested for anti-spike antibody titre (ASAb; positive ≥ 0.80 U/mL) and neutralizing antibody (NAb; positive ≥20% neutralization) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as number (proportion) and median (interquartile range) and compared using non-parametric tests. Results: Overall, 99.2% and 84% patients developed ASAb (titre 5440 (1719–9980 U/mL)) and NAb (92 (49.1–97.6%)), respectively. When comparing between the study groups, the ASAb titres were significantly higher in group II than in group I (2613 (310–7518) versus 6365 (2968–9463), p = 0.027) but were comparable between group II and III (6365 (2968–9463) versus 5267 (1739–11,653), p = 0.999). Similarly, NAb was higher in group II than in group I (95.5 (57.6–98.0) versus 45.9 (15.4–92.0); p < 0.001), but not between the groups II and III (95.5 (57.6–98.0) versus 92.4 (73.8–97.5); p = 0.386). Conclusion: Covishield(®) induces high titres of ASAb and NAb in cirrhosis. A higher titre is achieved if two doses are given at an interval of more than six weeks. |
format | Online Article Text |
id | pubmed-9696004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96960042022-11-26 Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis Goel, Amit Verma, Alka Tiwari, Prachi Katiyar, Harshita Aggarwal, Amita Khetan, Dheeraj Mayank, Kishore, Ravi V. Krishna Kumar, Pankaj Singh, Thakur Prashant Sheikh, Sabreena Vaishnav, Manas Pathak, Piyush Shalimar, Vaccines (Basel) Article Introduction: Data are limited on antibody response to the ChAdOx1 nCoV-19 vaccine (AZD1222; Covishield(®)) in cirrhosis. We studied the antibody response following two doses of the ChAdOx1 vaccine, given 4–12 weeks apart, in cirrhosis. Methods: Prospectively enrolled, 131 participants (71% males; age 50 (43–58); alcohol-related etiology 14, hepatitis B 33, hepatitis C 46, cryptogenic 21, autoimmune 9, others 8; Child–Turcott–Pugh class A/B/C 52/63/16). According to dose intervals, the participants were grouped as ≤6 weeks (group I), 7–12 weeks (group II), and 13–36 weeks (group III). Blood specimens collected at ≥4 weeks after the second dose were tested for anti-spike antibody titre (ASAb; positive ≥ 0.80 U/mL) and neutralizing antibody (NAb; positive ≥20% neutralization) using Elecsys Anti-SARS-CoV-2 S (Roche) and SARS-CoV-2 NAb ELISA Kit (Invitrogen), respectively. Data are expressed as number (proportion) and median (interquartile range) and compared using non-parametric tests. Results: Overall, 99.2% and 84% patients developed ASAb (titre 5440 (1719–9980 U/mL)) and NAb (92 (49.1–97.6%)), respectively. When comparing between the study groups, the ASAb titres were significantly higher in group II than in group I (2613 (310–7518) versus 6365 (2968–9463), p = 0.027) but were comparable between group II and III (6365 (2968–9463) versus 5267 (1739–11,653), p = 0.999). Similarly, NAb was higher in group II than in group I (95.5 (57.6–98.0) versus 45.9 (15.4–92.0); p < 0.001), but not between the groups II and III (95.5 (57.6–98.0) versus 92.4 (73.8–97.5); p = 0.386). Conclusion: Covishield(®) induces high titres of ASAb and NAb in cirrhosis. A higher titre is achieved if two doses are given at an interval of more than six weeks. MDPI 2022-10-30 /pmc/articles/PMC9696004/ /pubmed/36366346 http://dx.doi.org/10.3390/vaccines10111837 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Goel, Amit Verma, Alka Tiwari, Prachi Katiyar, Harshita Aggarwal, Amita Khetan, Dheeraj Mayank, Kishore, Ravi V. Krishna Kumar, Pankaj Singh, Thakur Prashant Sheikh, Sabreena Vaishnav, Manas Pathak, Piyush Shalimar, Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis |
title | Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis |
title_full | Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis |
title_fullStr | Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis |
title_full_unstemmed | Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis |
title_short | Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis |
title_sort | serological immune response following chadox1 ncov-19 vaccine (covishield(®)) in patients with liver cirrhosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696004/ https://www.ncbi.nlm.nih.gov/pubmed/36366346 http://dx.doi.org/10.3390/vaccines10111837 |
work_keys_str_mv | AT goelamit serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT vermaalka serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT tiwariprachi serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT katiyarharshita serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT aggarwalamita serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT khetandheeraj serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT mayank serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT kishoreravivkrishna serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT kumarpankaj serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT singhthakurprashant serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT sheikhsabreena serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT vaishnavmanas serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT pathakpiyush serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis AT shalimar serologicalimmuneresponsefollowingchadox1ncov19vaccinecovishieldinpatientswithlivercirrhosis |